For patients with metastatic prostate cancer which is progressing despite androgen deprivation (by orchiectomy or treatment with a gonadotropin-releasing hormone agonist or antagonist) combined with an antiandrogen (abiraterone or enzalutamide), there are several possible options. These options consist of either continuing androgen suppression and replacing abiraterone with enzalutamide or vice versa, or offering chemotherapy using a taxane. The choice mainly depends on the treatments already received, the patients' response to these treatments and their general state of health (1-5).
展开▼
